Matthew Taylor

Assistant Professor

    • 1475 Citations
    • 7 h-Index
    20102017

    Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

    Neoplasms Medicine & Life Sciences
    Thyroid Neoplasms Medicine & Life Sciences
    nivolumab Medicine & Life Sciences
    ipilimumab Medicine & Life Sciences
    Melanoma Medicine & Life Sciences
    Therapeutics Medicine & Life Sciences
    lenvatinib Medicine & Life Sciences
    Placebos Medicine & Life Sciences

    Network Recent external collaboration on country level. Dive into details by clicking on the dots.

    Research Output 2010 2017

    • 1475 Citations
    • 7 h-Index
    • 11 Article
    • 1 Comment/debate

    Academic cancer center phase i program development

    Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N. S., Pishvaian, M. J., Thompson, J. A., Taylor, M. H., Mahadevan, D., Lockhart, A. C., Vaishampayan, U. N., Berlin, J. D., Smith, D. C., Sarantopoulos, J., Riese, M., Saleh, M. N., Ahn, C. & Frenkel, E. P. Apr 1 2017 In : Oncologist. 22, 4, p. 369-374 6 p.

    Research output: Research - peer-reviewComment/debate

    Program Development
    Neoplasms
    Research
    Research Personnel
    Clinical Trials
    1 Citations

    Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors

    Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M. H., Northfelt, D. W., Carson, W. E., Hawthorne, T. R., Davis, T. A., Yellin, M. J., Keler, T. & Bullock, T. Jun 20 2017 In : Journal of Clinical Oncology. 35, 18, p. 2028-2036 9 p.

    Research output: Research - peer-reviewArticle

    Anti-Idiotypic Antibodies
    Safety
    Neoplasms
    T-Lymphocytes
    Disease-Free Survival
    3 Citations

    Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer

    Robinson, B., Schlumberger, M., Wirth, L. J., Dutcus, C. E., Song, J., Taylor, M. H., Kim, S. B., Krzyzanowska, M. K., Capdevila, J., Sherman, S. I. & Tahara, M. Nov 1 2016 In : Journal of Clinical Endocrinology and Metabolism. 101, 11, p. 4103-4109 7 p.

    Research output: Research - peer-reviewArticle

    Thyroid Neoplasms
    Neoplasms
    lenvatinib
    Tumors
    Disease-Free Survival
    96 Citations

    Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    Hodi, F. S. , Chesney, J. , Pavlick, A. C. , Robert, C. , Grossmann, K. F. , McDermott, D. F. , Linette, G. P. , Meyer, N. , Giguere, J. K. , Agarwala, S. S. , Shaheen, M. , Ernstoff, M. S. , Minor, D. R. , Salama, A. K. , Taylor, M. H. , Ott, P. A. , Horak, C. , Gagnier, P. , Jiang, J. , Wolchok, J. D. & 1 others Postow, M. A. Nov 1 2016 In : The Lancet Oncology. 17, 11, p. 1558-1568 11 p.

    Research output: Research - peer-reviewArticle

    Melanoma
    Survival
    nivolumab
    ipilimumab
    Therapeutics
    125 Citations

    Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial

    Antonia, S. J. , López-Martin, J. A. , Bendell, J. , Ott, P. A. , Taylor, M. , Eder, J. P. , Jäger, D. , Pietanza, M. C. , Le, D. T. , de Braud, F. , Morse, M. A. , Ascierto, P. A. , Horn, L. , Amin, A. , Pillai, R. N. , Evans, J. , Chau, I. , Bono, P. , Atmaca, A. , Sharma, P. & 4 others Harbison, C. T., Lin, C. S., Christensen, O. & Calvo, E. 2016 (Accepted/In press) In : The Lancet Oncology.

    Research output: Research - peer-reviewArticle

    Small Cell Lung Carcinoma
    nivolumab
    ipilimumab
    Therapeutics
    Safety